Cargando…

Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome

XAF1 (X-linked inhibitor of apoptosis (XIAP)-associated factor 1) is a tumor suppressor that counteracts the anti-apoptotic effects of XIAP and can sensitize cells to cell death triggering events. XAF1 knockdown abrogated the temozolomide (TMZ)-induced G2-arrest and prevented TMZ-induced apoptosis i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reich, Thomas R., Switzeny, Olivier J., Renovanz, Mirjam, Sommer, Clemens, Kaina, Bernd, Christmann, Markus, Tomicic, Maja T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362468/ https://www.ncbi.nlm.nih.gov/pubmed/28122345 http://dx.doi.org/10.18632/oncotarget.14748

Ejemplares similares

MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response
por: Switzeny, Olivier J., et al.
Publicado: (2016)

Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding
por: Victoria-Acosta, Georgina, et al.
Publicado: (2015)

Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair
por: Christmann, Markus, et al.
Publicado: (2016)

Three prime exonuclease I (TREX1) is Fos/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo(a)pyrene-induced DNA damage
por: Christmann, Markus, et al.
Publicado: (2010)

Corrigendum: Epigenetic silencing of the XAF1 gene is mediated by the loss of CTCF binding
por: Victoria-Acosta, Georgina, et al.
Publicado: (2016)

c-Fos is required for excision repair of UV-light induced DNA lesions by triggering the re-synthesis of XPF
por: Christmann, Markus, et al.
Publicado: (2006)

Delayed c-Fos activation in human cells triggers XPF induction and an adaptive response to UVC-induced DNA damage and cytotoxicity
por: Tomicic, Maja T., et al.
Publicado: (2010)

Benzo[a]pyrene represses DNA repair through altered E2F1/E2F4 function marking an early event in DNA damage-induced cellular senescence
por: Allmann, Sebastian, et al.
Publicado: (2020)

Adaptive upregulation of DNA repair genes following benzo(a)pyrene diol epoxide protects against cell death at the expense of mutations
por: Christmann, Markus, et al.
Publicado: (2016)

Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment
por: Schwarzenbach, Christian, et al.
Publicado: (2021)

XAF1 expression and regulatory effects of somatostatin on XAF1 in prostate cancer cells
por: Xing, Zhaoquan, et al.
Publicado: (2010)

Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM
por: Tomicic, Maja T., et al.
Publicado: (2015)

XAFS for everyone
por: Calvin, Scott, et al.
Publicado: (2013)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Glycolytic expression in lower-grade glioma reveals an epigenetic association between IDH mutation status and PDL1/2 expression
por: Givechian, Kevin B, et al.
Publicado: (2020)

Silencing of the XAF1 gene by promoter hypermethylation in cancer cells and reactivation to TRAIL-sensitization by IFN-β
por: Micali, O Cristina, et al.
Publicado: (2007)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

Seizures in patients with IDH-mutated lower grade gliomas
por: Carstam, Louise, et al.
Publicado: (2022)

Computational Analysis of IDH1, IDH2, and TP53 Mutations in Low-Grade Gliomas Including Oligodendrogliomas and Astrocytomas
por: Bendahou, Mohammed Amine, et al.
Publicado: (2020)

Genetic Alteration Analysis of IDH1, IDH2, CDKN2A, MYB and MYBL1 in Pediatric Low-Grade Gliomas
por: Barinfeld, Orit, et al.
Publicado: (2022)

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells
por: Roos, Wynand P., et al.
Publicado: (2014)

Targeting anticancer drug-induced senescence in glioblastoma therapy
por: Tomicic, Maja T., et al.
Publicado: (2018)

XAFS Data Interchange: A single spectrum XAFS data file format
por: Ravel, B., et al.
Publicado: (2016)

The Value of Enhanced MR Radiomics in Estimating the IDH1 Genotype in High-Grade Gliomas
por: Niu, Lei, et al.
Publicado: (2020)

IDH1: Linking Metabolism and Epigenetics
por: Raineri, Silvia, et al.
Publicado: (2018)

Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Sun, Shanshan, et al.
Publicado: (2021)

IDH mutation-specific radiomic signature in lower-grade gliomas
por: Liu, Xing, et al.
Publicado: (2019)

PREOPERATIVE DETERMINATION OF IDH STATUS AND GRADE IN GLIOMAS USING MRS
por: Nguyen, Thanh Binh
Publicado: (2023)

Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas
por: Al-Ali, Ruslan, et al.
Publicado: (2019)

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade Glioma
por: Deng, Xiangyang, et al.
Publicado: (2019)

Association between preoperative neurocognitive status and IDH1 mutation status in high-grade gliomas
por: Liouta, Evangelia, et al.
Publicado: (2022)

XAF1 directs glioma response to temozolomide through apoptotic transition of autophagy by activation of ATM–AMPK signaling
por: Lee, Min-Goo, et al.
Publicado: (2022)

Paradoxical epigenetic regulation of XAF1 mediates plasticity towards adaptive resistance evolution in MGMT-methylated glioblastoma
por: Wu, Qiong, et al.
Publicado: (2019)

Improving the quality of XAFS data
por: Abe, Hitoshi, et al.
Publicado: (2018)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

IDH mutations but not TERTp mutations are associated with seizures in lower-grade gliomas
por: Duan, Wen-chao, et al.
Publicado: (2018)

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
por: Mellinghoff, Ingo K., et al.
Publicado: (2023)

Depatux-M and temozolomide in advanced high-grade glioma
por: Hirsch, Sophie, et al.
Publicado: (2020)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

The Significance of IDH1 Mutations in Tumor-Associated Seizure in 60 Chinese Patients with Low-Grade Gliomas
por: Liang, Ruofei, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_rql9h33h08lbgp8uufaf5sobc1